Category Archives: Investment

Wondering why some of your Pharma shares keep going up? Thank Trump’s tax “reform;” no, really.

The News: The drug industry has taken heat from patient advocates and a US senator for handing out its tax savings to shareholders instead of using its windfall to help patients… Read more »

2018 biotech IPOs still on a tear, with 25 already priced; 8 new filings last week alone.

In all my 26 years at MondayMorning, never have I witnessed such a massive, mad dash for the IPO filing window, and the SEC must be wondering if and when… Read more »

Weekly Medical Stock Spotlight: Group still outperforming other sectors. My take.

All three major US stock indices posted a weekly loss last week as the markets reacted to reports from the US-China trade summit, rising US government bond yields and increasing… Read more »

Biotech IPO rain dance continues and not just in the USA. My take on where to place your bets.

It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »

Insys attempting “Phoenix” impersonation as key Q1 earnings slated for Tuesday. Analysts say Buy, but is now the time?

The News: A former Insys Therapeutics Inc. (Chandler AZ) sales representative was recently sentenced to six months of home confinement after admitting that she participated in a scheme to pay… Read more »

Biotech IPO tsunami continues even as stocks sag following FDA chief’s drug-price rant.

The News: US Food and Drug Administration chief Scott Gottlieb on Thursday (May 3, 2018) questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law,… Read more »

Boomer Alert: Aging immune cells increase risk for macular degeneration, blindness. Apellis, Ophthotech to the rescue?

The News: As people age, so do their immune systems. And new research at Washington University School of Medicine in St. Louis suggests that aging immune cells increase the risk… Read more »

Innovent Biologics epitomizes how China, not Russia, quickly becoming real threat to US biotech supremacy.

The News: China’s Innovent Biologics Inc. has raised $150 million in a Series E crossover round, with Capital Group Private Markets picking up $90 million of the mega-round, according to Endpoints. The… Read more »

Healthcare stocks roar back after slump, while biotech IPOs continue stampede into pipeline.

The News: Rising healthcare stocks and fading qualms over an escalating Syrian conflict had Wall St. optimistic to start the week. Stocks had ended lower on Friday (April 13, 2018)… Read more »